Pharmaceutical

Civica Rx began construction in early 2021 on a $124.5 million pharmaceutical manufacturing center in Petersburg, Va. Created in collaboration with Phlow Corp., the 120,000-sf plant will produce sterile injectables for the treatment of COVID-19, emergency room and intensive-care unit treatments, surgeries, and other serious conditions. The facility will feature steam sterilization capabilities, disposable technologies, and advanced automation systems for visual inspection and packaging.

BioMed Realty is planning to create a life sciences innovation campus in Somerville, Mass. The project includes the renovation of an existing 162,000-sf office building and the construction of new facilities on an adjacent 7.5-acre parcel. Offering leasable environments for biomedical, pharmaceutical, and technology companies, the Assembly Square complex will provide 1.3 million sf of research, corporate, and retail space. The mixed-use development will feature multiple roof terraces and a one-acre public park. BioMed Realty acquired the property in early 2021.

Canadian developer Oxford Properties has expanded its real estate portfolio in the United States with the acquisition of four new assets. Representing an investment of $276 million in the burgeoning life sciences industry, the purchase included a total of 415,000 sf of existing space and associated developable land. Oxford Properties plans to spend an additional $500 million to repurpose, renovate, and expand the four structures to create leading-edge lab and office environments for biomedical tenants. 

Silverstein Properties & Cantor Fitzgerald are partnering with University Place Associates to create a biomedical innovation center in Philadelphia. Providing leading-edge lab and office facilities, 3.0 University Place is pre-certified as LEED Platinum v4 BD+C for core and shell, and will also target WELL Core v2 Platinum certification.

BioMed Realty is creating a 482,000-sf life sciences hub in Boston's Seaport District. Previously serving as the corporate headquarters of John Hancock, the building was acquired by BioMed Realty in late 2020. Featuring robust mechanical and electrical systems, the existing structure has attained LEED Platinum sustainable design certification and includes a variety of collaborative meeting areas. The facility will be renovated to provide sophisticated lab and office environments for biomedical companies. Occupancy is expected in the second half of 2022. 

Thermo Fisher Scientific is expanding its global production capacity for vaccines, medicines, and biologic therapies. Construction will begin in mid-2021 on a 130,000-sf facility in Greenville, N.C. Slated for completion in 2022, the standalone structure will accommodate two live-virus filling lines. The project is part of a $500 million investment in the site that will add six new lines in existing buildings to support commercial-scale liquid vial filling and the creation of lyophilized materials. 

Millennium Partners and Beacon Capital Partners will begin construction in late 2021 on a 380,000-sf life sciences facility in Boston. Designed by Handel Architects in collaboration with STUDIO ENÉE, the mixed-use development will provide leading-edge laboratories, offices, and R&D suites clustered around a collaborative open space. Located on 4.6 acres in the Raymond L. Flynn Marine Park, the eight-story project will feature a central core of corrugated metal to celebrate the area's industrial heritage.

Nationwide Children's Hospital is constructing a $100 million gene therapy manufacturing center in Columbus, Ohio. The 185,000-sf facility will enable Andelyn Biosciences, a for-profit subsidiary of Nationwide Children's, to supply pharmaceutical and biotechnology companies with genetic material for use in research and clinical trials. Located in The Ohio State University's Innovation District, the leased structure will feature advanced cGMP environments for commercial-scale manufacturing.

Stanford University dedicated the $210 million Biomedical Innovation Building in November of 2020 in Palo Alto, Calif. Designed by ZGF Architects with Research Facilities Design (RFD) as laboratory design consultant, the 190,439-gsf facility strategically collocates investigators with expertise in cardiovascular medicine, pediatrics, orthopaedics, immunotherapy, personalized genomics, otolaryngology, and asthma and allergy.

The Institute of Cancer Research (ICR) opened the £75 million Centre for Cancer Drug Discovery in London in November of 2020. Located in the borough of Sutton, the 78,580-sf facility features team laboratories where biologists, evolutionary scientists, chemists, pharmacologists, data scientists, and clinicians can discover new solutions for cancer evolution and drug resistance.

The University of Oregon dedicated the first phase of the Phil and Penny Knight Campus for Accelerating Scientific Impact in December of 2020 in Eugene. Designed by Ennead Architects and Bora Architects to encourage interaction and collaboration, the $225 million, 160,000-sf building offers leading-edge biomedical laboratories, core facilities, classrooms, and an innovation center.

ApiJect will break ground in December of 2020 on the Gigafactory campus in Durham, N.C. Strategically sited in Research Triangle Park, the complex will be the world’s largest pharmaceutical fill-finish facility, offering an annual production capacity of three billion single-dose prefilled injectors. Funded by a federal loan of $590 million, the one million-sf project will provide BSL-2 manufacturing areas, cold and ultra-cold storage infrastructure, and an onsite needle and cannula factory.

Alexandria Real Estate Equities has attained the world's first WELL Health-Safety Rating for laboratory space at Alexandria LaunchLabs in New York City. Augmenting the center’s existing WELL certification for building design, the WELL Health-Safety Rating for Facilities Operations and Management includes further measures to protect the health of tenants, employees, visitors, and service personnel. Protocols at Alexandria LaunchLabs include:

The University of Massachusetts Medical School is planning to construct the $325 million New Education and Research Building in Worcester. Accommodating 77 principal investigators, the nine-story, 350,000-sf facility will include space for animal research as well as housing an FDA-compliant manufacturing center for clinical trial therapeutics. The project will enable UMass to increase its class sizes help meet the needs of the commonwealth and the nation for physicians, graduate nurses, life sciences researchers, and other health sciences professionals.

The Centre for Process Innovation (CPI) began construction in October of 2020 on the Medicines Manufacturing Innovation Centre in Inchinnan in the United Kingdom. Created in collaboration with the University of Strathclyde, GSK, and AstraZeneca, the £42 million facility will enable the development of new pharmaceutical production methods that will be proven at scale in a GMP environment.